翼状胬肉术中应用bevacizumab与丝裂霉素C的比较

Comparative study of pterygium surgery combined with bevacizumab or mitomycin C

摘要:

目的：比较研究翼状胬肉手术联合bevacizumab与丝裂霉素C的临床疗效及其术后复发率和并发症情况。

方法：将2010-01/2012-01浙江省中西医结合医院眼科住院的翼状胬肉患者80例随机分为两组，A组40例采用手术联合球结膜下注射bevacizumab治疗，B组40例采用手术联合术中丝裂霉素C贴敷治疗，随访1a，比较评估两组的临床疗效及其术后复发率和并发症。

结果：A组治愈率为88%，B组为85%，两组临床疗效比较无显著差异(χ²=0.105，P>0.05)； A组术后复发率为12%，B组为15%，两组术后复发率比较无显著差异(χ²=0.105，P>0.05)； A组术后并发症发生率为2%，B组为18%，两组术后并发症比较有显著差异(χ²=4.517，P<0.05)。

结论：翼状胬肉手术联合bevacizumab与丝裂霉素C的临床疗效显著，术后复发率低，但联合bevacizumab并发症较少。

Abstract:

AIM: To observe and compare the clinical effect and postoperative recrudescence rate and complication of pterygium surgery combined with bevacizumab or mitomycin C.

METHODS: Eighty pterygium inpatients in the Department of Ophthalmology in Integrated Chinese and Western Medicine Hospital of Zhejiang Province from January 2010 to January 2012 were randomly divided into two groups. Forty cases in group A were treated by surgery combined with subconjunctival injection of bevacizumab, Forty cases in group B were treated by surgery combined with mitomycin C sticking therapy. After following up for 1 year, the curative effect and postoperative recurrence rate and complications were compared and evaluated between the two groups.

RESULTS: The cure rate of group A and B were 88%, 85%, respectively, demonstrating no significant difference(χ²=0.105, P>0.05); The postoperative recurrence rate of group A, B were 12%, 15%, respectively, the differences of which weren't significantly different(χ²=0.105, P>0.05); The incidence of postoperative complications in group A, B were 2%, 18%, the differences of which weren't significantly different(χ²=4.517, P<0.05).

CONCLUSION: The clinical effect of pterygium surgery combined with bevacizumab or mitomycin C is significant with a low postoperative recrudescence rate, but the former has fewer complications.